StockNews.com began coverage on shares of Organovo (NASDAQ:ONVO – Free Report) in a research note released on Friday morning. The brokerage issued a sell rating on the medical research company’s stock.
Organovo Stock Up 1.2 %
ONVO opened at $1.00 on Friday. Organovo has a fifty-two week low of $0.89 and a fifty-two week high of $2.05. The business has a 50-day moving average of $1.04 and a 200-day moving average of $1.12.
Organovo (NASDAQ:ONVO – Get Free Report) last posted its quarterly earnings results on Thursday, February 8th. The medical research company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.01. The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.08 million. As a group, sell-side analysts anticipate that Organovo will post -1.74 EPS for the current fiscal year.
Organovo Company Profile
Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Featured Stories
- Five stocks we like better than Organovo
- Why Invest in High-Yield Dividend Stocks?
- MarketBeat Week in Review – 4/22 – 4/26
- The How and Why of Investing in Biotech Stocks
- 3 Stocks Leading the U.S. Agriculture Comeback
- Options Trading – Understanding Strike Price
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.
